Overexpressing Bladder Cancer

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2022-08-10
Clinical Trial Update: Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable [Phase 2]
Phase 2 trial evaluating disitamab vedotin combined with tislelizumab for Her2-overexpressing high-risk non-muscle invasive bladder urotheli…